发明名称 |
Treatment of coagulation disease by administration of recombinant VWF |
摘要 |
The present invention provides methods of treating coagulation disease, including hemophilia and von Willebrand disease by administering recombinant von Willebrand Factor alone or in combination with Factor VIII. |
申请公布号 |
US9272021(B2) |
申请公布日期 |
2016.03.01 |
申请号 |
US201213493926 |
申请日期 |
2012.06.11 |
申请人 |
Baxalta Incorporated;Baxalta GmbH |
发明人 |
Scheiflinger Friedrich;Turecek Peter;Ewenstein Bruce;Wong Wing Yen;Suiter Tobias M. |
分类号 |
A61K38/36;A61P7/02;A61K38/37 |
主分类号 |
A61K38/36 |
代理机构 |
Morgan Lewis & Bockius LLP |
代理人 |
Morgan Lewis & Bockius LLP |
主权项 |
1. A method for treating Von Willebrand Disease or Hemophilia A in a subject in need thereof, the method comprising: intravenously administering to the subject a composition comprising recombinant Von Willebrand Factor (rVWF) wherein endogenous Factor VIII half-life is extended as compared to a subject administered plasma derived Von Willebrand Factor, wherein the rVWF is not modified with a water soluble polymer, wherein the composition is a high molecular weight VWF multimer composition comprising at least 20% VWF decamers or higher order multimers, and wherein the rVWF has a higher specific activity than plasma derived Von Willebrand Factor, and the higher order rVWF multimers are stable for at least 3 hours post-administration. |
地址 |
Bannockburn IL US |